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INTRODUCTION
Although aggressive combination chemotherapy for adult
acute lymphoblastic leukemia (ALL) has improved the com-
plete response (CR) rates, long-term survival rates seldom
exceed 40 percent (1-5). An intensive regimen developed by
the Cancer and Leukemia Group B (CALGB) has shown an
85% CR rate. However, the overall survival (OS) rate has not
improved significantly (1, 6). The CALGB study 19802 was
started based on the hypothesis that a post-remission inten-
sification regimen for eradicating the minimal residual disease
could increase OS (7). The preliminary experience with the
CALGB 19802 regimen for adults ALL demonstrated that
the post-remission regimen was feasible with acceptable side
effects (7).
The intensive use of L-asparaginase, during the postinduc-
tion period, was found to improve the cure rate in childhood
ALL (8, 9). However, this agent is difficult to deliver to adults
and also need frequent blood tests focusing on the coagula-
tion system and serum amylase because of significant toxici-
ty (5, 10-12). We evaluated a modified CALGB 19802 regi-
men that omitted L-asparaginase from the original CALGB
19802 regimen in adult ALL. Here, we present our results
on the efficacy and toxicity of the modified CALGB 19802
regimen.
MATERIALS AND METHODS
Patients
From February 2002 to August 2005, 25 adults with un-
treated ALL were enrolled in this study. The diagnosis of ALL
was based on morphology, histochemical stains, and immuno-
phenotyping. Cytogenetic and molecular analyses were per-
formed. The clinical records were reviewed to evaluate treat-
ment outcomes and toxicity.
Treatment
Treatment consisted of six courses given in the order A-B-
C-A-B-C followed by 18 months of a maintenance phase (7).
Induction chemotherapy (course A) consisted of cyclophos-
phamide, daunorubicin, vincristine, and prednisolone. Gra-
nulocyte colony-stimulating factor (G-CSF) was started when
the absolute neutrophil count (ANC) decreased below 500/ L.
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Outcomes of a Modified CALGB 19802 Regimen in Adult Acute
Lymphoblastic Leukemia
We analyzed the efficacy and toxicity of a modified Cancer and Leukemia Group B
(CALGB) 19802 regimen in adult acute lymphoblastic leukemia (ALL). From Febru-
ary 2002 to August 2005, 25 adults with untreated ALL were enrolled in the study.
Compared to the original regimen, the modified CALGB 19802 regimen consisted of
a 4-drug induction (cyclophosphamide, daunorubicin, vincristine, and prednisone)
instead of a 5-drug induction (L-asparaginase was added to the previous regimen).
This was followed by high-dose methotrexate (1,000 mg/m
2× ×3 days) and cytara-
bine (2,000 mg/m
2× ×4 days) for the consolidation cycles. High-dose systemic and
intrathecal methotrexate was given for central nervous system prophylaxis. Twenty-
three patients (92%) achieved a complete remission (CR), and two patients (8%)
had refractory disease. With a median follow-up of 21.5 months, 10 patients (40%)
were alive and continued to be in CR. The 3-yr probability of an event-free survival
and the overall survival were 39.0% and 47.4%, respectively. Treatment related
mortality and major grade 3 to 4 neurotoxicity occurred in 1 patient and 3 patients,
respectively. The modified CALGB 19802 regimen demonstrated a high remission
rate and a favorable survival rate.
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This was a modified CALGB 19802 regimen with the removal
of L-asparaginase and change of the schedule for G-CSF admin-
istration.
Post-remission therapy included five courses of consolidation
chemotherapy. Course B consisted of cyclophosphamide (1,000
mg/m2 on day 1) and high-dose cytarabine (2,000 mg/m2 on
days 1-4). G-CSF was started when ANC decreased below 500/
L. Course C consisted of intravenous high-dose methotrex-
ate (1,000 mg/m2 on days 1, 8, and 15) and vincristine (2 mg
on day 1, 8, and 15). Oral methotrexate (25 mg/m2) was
taken every six hours for four doses, starting 6 hr after the
beginning of the intravenous methotrexate. Oral leucovorin
(10 mg) was continued every 12 hr until the methotrexate
levels measured fell below 0.05  M.
At the end of 6 courses of A, B, and C chemotherapy,
patients received maintenance chemotherapy on a monthly
basis: prednisone 60 mg/m2 on day 1-5, intravenous vin-
cristine 2 mg on day 1, oral methotrexate 20 mg/m2 week-
ly, and oral 6-mercaptopurine 60 mg/m2 daily.
CNS prophylaxis was provided with intrathecal methotrex-
ate plus hydrocortisone. The first dose was given on day 1 of
cycle B. The subsequent doses were given on days 1, 8, and
15 of cycle C with systemic high-dose methotrexate.
Response criteria
Bone marrow aspiration and biopsy were performed at the
end of the induction phase. Patients were considered to be
in CR when the ANC was more than 1,000/ L, the platelet
count was higher than 100,000/ L, the bone marrow mor-
phology was normal with less than 5% blasts, there was no evi-
dence of extramedullary leukemia, and there was resolution
of the previously abnormal cytogenetics.
Statistical analysis
Event-free survival (EFS) was defined as the time from diag-
nosis to induction failure, relapse, or death. Patients who did
not achieve remission were included in the analysis and con-
sidered as treatment failures with an EFS of 0 days. OS was
measured from the date of diagnosis to the date of death or
the last follow-up visit. Six patients received stem cell trans-
plantation (SCT) were censored. The Kaplan-Meier product-
limit method was used to estimate the EFS and the OS. The
survival rates were compared using the log-rank test. Differ-
ences were considered statistically significant when p<0.05.
RESULTS
Patients
Clinical and hematological characteristics of the 25 patients
are summarized in Table 1. The median age of all patients
was 45 yr (range, 18 to 68 yr), and five (20%) patients were
older than 60. Hepatosplenomegaly was present in 10 (40%)
patients. Five (20%) patients had mediastinal involvement.
Two patients (8%) had evidence of CNS leukemia at the time
of diagnosis. The median initial WBC count was 12.24×109/L
(range, 2.0-149), and eight (32%) patients had an initial WBC
count higer than 30×109/L. Immunophenotype analysis sh-
owed that 18 (72%) patients had B-lineage ALL and 7 (28%)
patients had T-lineage ALL. Chromosomal analysis was avail-
able in all patients, and the philadelphia (Ph) chromosome
was found in nine (36%) patients. No patient had t(4;11).
Remission induction
CR was achieved in 23 patients (92%), while 2 (8%) had
refractory disease. Remission was achieved with the first course
of treatment in 22 patients and required a second course of
treatment in one. The median time to achieve CR was 24
days (range, 17-86).
Postremission therapy
Among the 23 eligible patients who achieved CR, three
patients could not receive the consolidation therapy due to
relapse (n=2) or infection (n=1). Among the 20 patients who
received the consolidation therapy, only 10 patients complet-
ed the consolidation therapy. The reasons for an incomplete
Characteristics No. of patients (%)
Total 25
Male 12 (48)
Female 13 (52)
Median age 45 yr (range, 18-68)
<30 8 (32)
30-59 12 (48)
60 5 (20)
Clinical features
Fever 7 (28)
Mediastinal mass 5 (20)
Hepatosplenomegaly 10 (40)
CNS involvement 2 (8)
Hematological parameters
WBC count >30,000/ L 8 (32)
Platelet count <100,000/ L 19 (70)
Hemoglobin level <10 g/dL 12 (44)
Immunophenotype
B cell lineage 18 (72)
T cell lineage 7 (28)
Cytogenetics
t(9;22) 9 (36)
Risk of relapse
Standard 12 (48)
High 13 (52)
Table 1. Patient characteristics
CNS, central nervous system; WBC, white blood cells.280 A.-R. Han, K. Kim, J.H. Jang, et al.
consolidation therapy were stem cell transplantation in 6
patients, death in 1 patient, drug toxicity in 1 patient, and
relapse during consolidation in 2 patients. Among the 10
patients who completed the consolidation therapy, six patients
did not enter the maintenance therapy due to relapse (n=3),
drug toxicity (n=2), or patient refusal (n=1). Of the four
patients who entered the maintenance therapy, three patients
completed maintenance therapy. One patient could not com-
plete the maintenance therapy due to death.
Treatment outcome 
At a median follow-up period of 22 months (range, 2 to
47 months), 10 patients (40%) are alive and continue to be
in CR. Three patients (12%) died in remission. Seven patients
(30%) among 23 patients who achieved CR relapsed. There
was no case of an isolated CNS relapse. Six patients (24%)
received SCT during the first CR: 5 allogenic SCT, 1 autol-
ogous SCT. One patient (4%) received SCT after relapse.
Patients who received SCT were censored at the time of the
transplantation. Of the nine patients with a Ph chromosome,
three patients were treated with imatinib mesylate. Among
them, two patients received imatinib mesylate monothera-
py after reinduction chemotherapy due to relapse (n=1) and
refractory state (n=1), and 1 patient received imatinib mesy-
late monotherapy after induction. For all 25 patients, the
estimated 3-yr EFS and OS were 39.0% and 47.4%, respec-
tively (Fig. 1, 2).
There were no significant prognostic factors identified in
the univariate and multivariate analysis (Table 2).
Number of episodes (%)
ABC M
(39 cycles) (34 cycles) (28 cycles) (4 cycles)
Hematologic toxicity
Grade 3 0 0 6 (21%) 0
Grade 4 35 (90%) 32 (94%) 6 (21%) 0
Infection toxicity
Grade 3 4 (10%) 25 (74%) 11 (39%) 1
Grade 4 25 (64%) 0 0 0
GI toxicity
Grade 3 1 (3%) 0 1 (4%) 0
Grade 4 0 0 0 0
Hepatic toxicity
Grade 3 0 2 (6%) 2 (7%) 0
Grade 4 2 (5%) 0 2 (7%) 0
Neurological toxicity
Grade 3 0 0 0 0
Grade 4 0 1 (3%) 2 (7%) 0
Table 3. Number of grade 3 or 4 toxicities associated with each
course of treatment
Fig. 1. Kaplan-Meier plots of overall survival.
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Fig. 2. Kaplan-Meier plots of event-free survival.
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Factors Overall survival p EFS p
Age (<30 vs. 30-59 vs. 60) .560 .242
Gender (male vs. female) .456 .485
Peripheral lymphadenopathy .698 .748
Mediastinal mass .964 .860
Hepatosplenomegaly .446 .334
WBC counts (<30,000 vs. 30,000/ L) .925 .569
t(9;22) .067 .210
Immunophenotype (B vs. T cell lineage) .981 .939
Time to CR ( 30 d vs. >30 d) .434 .955
CNS involvement .261 .235
Table 2. Prognostic factors for overall survival and event-free sur-
vival (univariate analysis)
WBC, white blood cells; CR, complete remission; CNS, central nervous
system.
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Toxicity
The major toxicity after induction and consolidation chemo-
therapy was hematotoxicity (Table 3). Hematotoxicity occurred
frequently during cycles A and B. The median time to recov-
ery of the ANC to higher than 1,000/ L was 16, 17, and 20.5
days during cycles A, B, and C, respectively. The median time
to recovery of the platelet count to higher than 100,000/ L
was 22.5, 26.5, and 33 days during cycles A, B, and C, respec-
tively. The second most common toxicity was infection. There
were 33 documented infections (19 bacterial, 8 fungal, and
6 viral infections) and 33 cases of febrile neutropenia (fever
of unknown origin without documented infection). Both
the frequency and severity of the infections were highest dur-
ing cycle A. Neurological toxicity occurred in 3 patients.
Among them, one patient developed cerebellar dysfunction
attributable to the high-dose cytarabine during the first cycle
B. In addition, two patients developed myelopathy after
intrathecal methotrexate administration during the second
cycle C. Although they received the appropriate manage-
ment, none of them improved and they could not continue
chemotherapy.
DISCUSSION
The CALGB 19802 regimen is characterized by early dose
intensification of daunorubicin during induction and post-remis-
sion therapy and high-dose cytarabine and methotrexate dur-
ing post-remission therapy. This regimen aims to improve
survival in adults with ALL by dose intensification using agents
already known to be effective in ALL (7). In a recent update of
the CALGB 19802 regimen, the median survival period was
1.6 yr and the median disease-free survival period was 1.5 yr.
This regimen showed no improvement in the OS and the EFS
compared with other studies (13-17). Although our modified
CALGB 19802 regimen omitted L-asparaginase from the
CALGB 19802 regimen, it followed the characteristics of orig-
inal regimen, identically. In our study, the modified CALGB
19802 regimen resulted in a high CR rate and a favorable EFS
and OS. The difference in outcomes, compared with the
original CALGB 19802 regimen, could be due to one or
more of the following factors: a small number of patients,
no removal of cyclophosphamide from the A cycle in older
patients, or the inclusion of patients who had SCT. Recent
nonrandomized studies showed that intensive consolidation
therapy improved the outcome with the use of cyclophos-
phamide and high-dose cytarabine (10, 18). However, inten-
sified anthracycline has shown no clear benefit in adults (3,
19). Considering the small number of patients and the ret-
rospective nature of the study, the value of the individual
components of the modified 19802 regimen could not be
confirmed in this study.
L-asparaginase has an established role in the treatment of
childhood ALL (9, 20). Although several clinical trials using
L-asparaginase in adult ALL have been reported, it is difficult
to evaluate the true impact of L-asparaginase in the treatment
strategy for adult ALL because L-asparaginase was given with
other drugs simultaneously (21, 22). Nagura et al. showed no
significant difference in the CR rate and the OS between induc-
tion chemotherapy with and without L-asparaginase in a ran-
domized clinical trial on adult ALL (23). These findings are
consistent with our results; our study showed no significant
difference in the CR rate and the OS compared with other
studies using L-asparaginase (3, 6, 24). However, a recent
study showed that effective asparagines depletion with pegy-
lated asparaginase, as part of an intensive multiagent thera-
peutic regimen in adult ALL, was feasible and associated
with improved outcomes (25). In comparison with previous
studies, this discrepancy may be attributed to differences in
dose intensity and duration of asparaginase therapy. Larger
patient cohorts are required to determine the true impact of
L-asparaginase in the treatment of adult ALL.
There was no CNS relapse in cases without cranial radiation
for CNS prophylaxis. However, grade 4 neurotoxicity occurred
in three (12%) patients. Among them, cerebellar toxicity due
to cytarabine was found in a 66-yr-old man after receiving
his first course of cycle B chemotherapy. Two other patients
had myelopathy after receiving intrathecal methotrexate
during the second cycle C. Although it was difficult to deter-
mine the precise incidence of the neurotoxicities for the ALL
therapy in adults due to the heterogeneity, grade 3 to 4 neu-
rotoxicities occurred more frequently and were more severe
than in other studies (7, 10, 18, 26). Considering the high
median age of the patient population, the CNS toxicity with
high-dose cytarabine was acceptable. However, we cannot
account for the high occurrence of the neurotoxicity related
to methotrexate because the etiology of methotrexate toxici-
ty remains uncertain (27). Further studies are necessary to
evaluate the prognostic factors for neurological events linked
to methotrexate.
The modified CALGB19802 regimen produced a high re-
mission rate and a favorable survival rate. However, this study
has several limitations including the small number of patients,
the retrospective study design, and the relatively short follow-
up duration. Therefore, further studies with a longer follow-
up and randomized study design are needed to confirm the
benefit on OS and EFS. 
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